Virtual Library
Start Your Search
Tomoyuki Igarashi
Author of
-
+
P1.02 - Biology/Pathology (ID 614)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.02-030 - The Effect of Chronic Obstructive Pulmonary Disease on the Tumor Stroma in Non-Small Cell Lung Cancer (ID 9215)
09:30 - 16:00 | Author(s): Tomoyuki Igarashi
- Abstract
Background:
Inflammatory cytokines, including tumor necrosis factor-α (TNFα), interleukin(IL)-6, IL-8, and IL-18 in the blood are elevated in patients with chronic obstructive pulmonary disease (COPD), but the influence of COPD on the differentiation and function of cancer-associated fibroblasts (CAFs), which are the dominant stromal component in the tumor microenvironment, remains to be elucidated in non-small cell lung cancer (NSCLC) patients. The purpose of this study is to examined the relationship between degree of COPD and CAFs in NSCLC patients who had undergone the lung surgery.
Method:
The expression of αSMA in tumor tissue was analyzed by immunohistochemistry for 45 cases with COPD and 8 cases without COPD who had undergone lung cancer surgery between 2014 and 2015 to evaluate the frequency of CAFs. We evaluated the correlations between low attenuation area (LAA), Brinkman index (BI), FEV1/FVC, GOLD COPD Stages and frequency of CAFs in tumor tissue.
Result:
Univariate analysis showed a strong correlation between the frequency of CAFs and LAA (P＜0.001), BI (P＜0.001), FEV1/FVC (P＜0.001) except for GOLD COPD Stages (P=0.208). Multivariate analysis showed that LAA was significant predictors of frequency of CAFs in tumor tissue.
Conclusion:
Parameters obtained from the pulmonary function test and smoking index are often affected by the skill and memory of the patients. It was suggested that the LAA which objectively quantified the degree of emphysematous change was more related by the frequency of CAFs in tumor microenvironment.
-
+
P1.03 - Chemotherapy/Targeted Therapy (ID 689)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.03-037 - A Phase II Study of Adjuvant Chemotherapy with Docetaxel plus Nedaplatin for Completely Resected Non-Small Cell Lung Cancer (ID 9631)
09:30 - 16:00 | Author(s): Tomoyuki Igarashi
- Abstract
Background:
Nedaplatin, a cisplatin derivative, has similar activity to cisplatin for non-small-cell lung cancer (NSCLC). We previous reported that the combination chemotherapy of docetaxel plus nedaplatin was well tolerated in patients with advanced NSCLC. The purpose of this phase II study was to evaluate the feasibility of combination chemotherapy of docetaxel plus nedaplatin as an adjuvant chemotherapy in patients with completely resected stage IB-IIIA NSCLC.
Method:
Following a radical surgery, patients were treated with docetaxel (60 mg/m[2]) and nedaplatin (80 mg/m[2]) on day 1 every four weeks up to four cycles. The primary endpoint was feasibility, determined by the proportion of patients who completed four cycles of the combination chemotherapy. Adverse events were graded according to National Cancer Institute Common Toxicity Criteria (version 4.0). Median relapse-free survival time after surgery was calculated by analyzed by Kaplan-Meier analysis.
Result:
From December 2010 and April 2016, 34 patients with median age of 64.5 years (range, 36–77 years) were enrolled in this study. The patients consisted of 30 males and four females. Histological types were adenocarcinomas in 20 patients, squamous cell carcinomas in 12, and others in 2. Pathological stages were IB in 2 patients, II in 21, and IIIA in 11. Concerning the feasibility of the combination adjuvant chemotherapy, twenty-six patients (76.5%) completed four cycles of the combination chemotherapy. In 11 of those patients (42.3%), doses of the agents were decreased from the initial doses due to toxicities. Grade 3 or 4 toxicities included leukopenia (36.4%), neutropenia (69.5), anemia (1.7%), thrombocytopenia (0.8%), anorexia (7.6%), and nausea (3.4%). There were no treatment-related deaths. Median relapse-free survival time after the surgery was not reached, and 5-year survival rate was 65.8%.
Conclusion:
Given high completion rate of adjuvant chemotherapy with docetaxel plus nedaplatin, we conclude that the adjuvant chemotherapy is feasible and tolerable in patients with completely resected NSCLC.
-
+
P3.02 - Biology/Pathology (ID 620)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.02-003 - Tissue and Serum Levels of Galectin-3 in NSCLC Patients (ID 8723)
09:30 - 16:00 | Author(s): Tomoyuki Igarashi
- Abstract
Background:
Galectin-3 is a β-galactoside binding lectin, which is associated with cell proliferation, cell adhesion, apoptosis, angiogenesis and metastasis in several types of malignancies. However, the role of galectin-3 in the prognosis of lung cancer remains to be elucidated. In this study, we examined whether tissue expression and serum level of galectin-3 could serve as a prognostic marker in NSCLC.
Method:
Galectin-3 expression was analyzed by immunohistochemistry for 42 NSCLC patients who had undergone the radical surgery between 2014 and 2016. Serum galectin-3 level was assessed before surgery and 1 month after surgery by the enzyme-linked immunosorbent assay method.
Result:
Galectin-3 expression was observed in 14 patients (33.3%), and significantly associated with the incidence of recurrences (p<0.001) and the relapse-free survival time (p<0.001). Serum galectin-3 level was not reduced after radical resection, and there was no significant correlation between tissue expression and serum level of galectin-3.
Conclusion:
These data suggest that galectin-3 expression on tumor cells would serve as a prognostic marker in NSCLC, but serum galectin-3 level has no prognostic role on recurrence.
-
+
P3.16 - Surgery (ID 732)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Surgery
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.16-048 - The Role of Pulmonary Resection in Stage IVa Non-Small Cell Carcinoma Patients (ID 9907)
09:30 - 16:00 | Presenting Author(s): Tomoyuki Igarashi
- Abstract
Background:
In non-small cell lung cancer (NSCLC), pulmonary resection for stage IV patients was not recommended in standard therapy. However, various new treatments for advanced or recurrence NSCLC patients such as molecular-targeted therapy for driver oncogenes or immune checkpoint therapy have improved the survival of those patients in these days. Therefore, we need to review the role of surgery for advanced NSCLC patients again.
Method:
Clinical records of 334 patient diagnosed stage IV in Shiga University of Medical Science between 2006 and 2015 were reviewed and clinicopatholocgial features and overall survival were analyzed retrospectively.
Result:
32 patients underwent surgery in this period, and the patients included 25 men and 7 women, with median age of 70.0 years (52-82 years). There were 22 adenocarcinomas, 8 squamous cell carcinomas and 2 other histological subtypes. Surgery included 19 pulmonary resections, 3 spinal fixation surgery, 7 intracranial surgery and 3 other surgery. Median overall survival following surgery or non-surgery was 15.8 month and 9.9 months, respectively (P=0.002). Moreover, in 19 cases of pulmonary resection, there were 7 patients with pleural disseminations (IVa) and 12 patients with distant metastases (IVb). In case with disseminations (IVa), median overall survival was also significantly longer in patients with pulmonary resection than in those of non-operative 31 patients in the same period (42.2 months vs 8.3 months, P=0.038).
Conclusion:
Although further study in larger sets of patients would be warranted, surgery should not be excluded from treatment modality for stage IV patients, especially IVa cases if we could selected appropriately.
